Piperlongumine reverses doxorubicin resistance through the PI3K/Akt signaling pathway in K562/A02 human leukemia cells

Experimental and Therapeutic Medicine

Volumn 9, Issue 4, 2015, Pages 1345-1350

  Kang, Qingwei ^a   Yan, Shu ^a  

^a TIANJIN NANKAI HOSPITAL   (China)

Author keywords

Doxorubicin resistance; Human leukemia; Piperlongumine

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PIPERLONGUMINE; PROTEIN KINASE B; PROTEIN P27; PROTEIN P53; REACTIVE OXYGEN METABOLITE; RHODAMINE 123; SURVIVIN; TRANSCRIPTION FACTOR TWIST; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL PROLIFERATION; DRUG SENSITIVITY; FLOW CYTOMETRY; GENETIC ANALYSIS; HUMAN; HUMAN CELL; LEUKEMIA; LUCIFERASE ASSAY; MTS ASSAY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84922969196     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2015.2254     Document Type: Article

References (26)

1. Mardiros A, Brown CE, Budde LE, Wang X and Forman SJ: Acute myeloid leukemia therapeutics: CARs in the driver's seat. Oncoimmunology 12: e27214, 2013.
2. Joshi I, Yoshida T, Jena N, Qi X, Zhang J, Van Etten RA and Georgopoulos K: Loss of Ikaros DNA binding function confers integrin dependent survival on pre B cells and progression to acute lymphoblastic leukemia. Nat Immunol 15: 294-304, 2014.
3. Rashid A, Lee NG, Jakobiec FA and Freitag SK: Epstein-Barr virus-positive polymorphous lymphoplasmacytic infiltrate of the lacrimal glands in a patient with acute lymphoblastic leukemia. JAMA Ophthalmol 132: 892-894, 2014.
4. Yuasa M, Ishiwata K, Sugio T, et al: Herpes simplex virus type 2 fulminant hepatitis after umbilical cord blood transplantation for acute myeloid leukemia. Rinsho Ketsueki 55: 682-686, 2014 (In Japanese).
5. Shamroe CL and Comeau JM: Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. Ann Pharmacother 11: 1540-1546, 2013.
6. Badura S, Tesanovic T, Pfeifer H, Wystub S, Nijmeijer BA, Liebermann M, Falkenburg JH, Ruthardt M and Ottmann OG: Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia. PLoS One 11: e80070, 2013.
7. Han SS, Han S and Kamberos NL: Piperlongumine inhibits the proliferation and survival of B-cell acute lymphoblastic leukemia cell lines irrespective of glucocorticoid resistance. Biochem Biophys Res Commun 452: 669-675, 2014.
8. Pei S, Minhajuddin M, Callahan KP, et al: Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells. J Biol Chem 288: 33542-33558, 2013.
9. Makhov P, Golovine K, Teper E, Kutikov A, Mehrazin R, Corcoran A, Tulin A, Uzzo RG and Kolenko VM: Piperlongumine promotes autophagy via inhibition of Akt/mTOR signalling and mediates cancer cell death. Br J Cancer 110: 899-907, 2014.
10. Ginzburg S, Golovine KV, Makhov PB, Uzzo RG, Kutikov A and Kolenko VM: Piperlongumine inhibits NF κB activity and attenuates aggressive growth characteristics of prostate cancer cells. Prostate 2: 177-186, 2014.
11. Liu Y, Chang Y, Yang C, et al: Biodegradable nanoassemblies of piperlongumine display enhanced anti-angiogenesis and anti-tumor activities. Nanoscale 6: 4325-4337, 2014.
12. Vasconcelos FC, Nestal de Moraes G, Moellmann Coelho A and Maia RC: Phosphorylated Crkl reduction levels are associated with the lowest P glycoprotein activity levels in cells from chronic myeloid leukemia patients. Leuk Res 12: 1711-1718, 2013.
13. Doroshow JH: Overcoming resistance to targeted anticancer drugs. N Engl J Med 19: 1852-1853, 2013.
14. Ariës IM, Hansen BR, Koch T, van den Dungen R, Evans WE, Pieters R and den Boer ML: The synergism of MCL1 and glycolysis on pediatric acute lymphoblastic leukemia cell survival and prednisolone resistance. Haematologica 12: 1905-1911, 2013.
15. Daflon Yunes N, Pinto Silva FE, Vidal RS, Novis BF, Berguetti T, Lopes RR, Polycarpo C and Rumjanek VM: Characterization of a multidrug resistant chronic myeloid leukemia cell line presenting multiple resistance mechanisms. Mol Cell Biochem 1-2: 123-135, 2013.
16. Wang JY, Yu P, Chen S, Xing H, Chen Y, Wang M, Tang K, Tian Z, Rao Q and Wang J: Activation of Rac1 GTPase promotes leukemia cell chemotherapy resistance, quiescence and niche interaction. Mol Oncol 5: 907-916, 2013.
17. Karami H, Baradaran B, Esfahani A, Estiar MA, Naghavi-Behzad M, Sakhinia M and Sakhinia E: siRNA-mediated silencing of survivin inhibits proliferation and enhances etoposide chemosensitivity in acute myeloid leukemia cells. Asian Pac J Cancer Prev 12: 7719-7724, 2013.
18. Shi X, Chen X, Li X, Lan X, Zhao C, Liu S, Huang H, Liu N, Liao S, Song W, Zhou P, Wang S, Xu L, Wang X, Dou QP and Liu J: Gambogic acid induces apoptosis in imatinib resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase dependent Bcr Abl downregulation. Clin Cancer Res 1: 151-163, 2014.
19. Chromik J, Safferthal C, Serve H and Fulda S: Smac mimetic primes apoptosis resistant acute myeloid leukaemia cells for cytarabine induced cell death by triggering necroptosis. Cancer Lett 1: 101-109, 2014.
20. Rahgozar S, Moafi A, Abedi M, Entezar E Ghaem M, Moshtaghian J, Ghaedi K, Esmaeili A and Montazeri F: mRNA expression profile of multidrug resistant genes in acute lymphoblastic leukemia of children, a prognostic value for ABCA3 and ABCA2. Cancer Biol Ther 1: 35-41, 2014.
21. Ma H, Cheng L, Hao K, Li Y, Song X, Zhou H and Jia L: Reversal effect of ST6GAL 1 on multidrug resistance in human leukemia by regulating the PI3K/Akt pathway and the expression of P gp and MRP1. PLoS One 1: e85113, 2014.
22. Shrivastava S, Kulkarni P, Thummuri D, Jeengar MK, Naidu VG, Alvala M, Redddy GB and Ramakrishna S: Piperlongumine, an alkaloid causes inhibition of PI3 K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triple-negative breast cancer cells. Apoptosis 7: 1148-1164, 2014.
23. Liu Z, Zhang YY, Zhang QW, Zhao SR, Wu CZ, Cheng X, Jiang CC, Jiang ZW and Liu H: 3 Bromopyruvate induces apoptosis in breast cancer cells by downregulating Mcl 1 through the PI3K/Akt signaling pathway. Anticancer Drugs 4: 447-455, 2014.
24. Reikvam H, Tamburini J, Skrede S, Holdhus R, Poulain L, Ersvaer E, Hatfield KJ and Bruserud Ø: Antileukaemic effect of PI3K mTOR inhibitors in acute myeloid leukaemia gene expression profiles reveal CDC25B expression as determinate of pharmacological effect. Br J Haematol 2: 200-211, 2014.
25. Kim MS, Kim GM, Choi YJ, Kim HJ, Kim YJ and Jin W: TrkC promotes survival and growth of leukemia cells through Akt mTOR dependent up regulation of PLK 1 and Twist 1. Mol Cells 2: 177-184, 2013.
26. Pede V, Rombout A, Vermeire J, Naessens E, Vanderstraeten H, Philippé J and Verhasselt B: Expression of ZAP70 in chronic lymphocytic leukaemia activates NF κB signalling. Br J Haematol 5: 621-630, 2013.